CVX vs PFE: Which Is the Better Buy?

Side-by-side comparison of Chevron Corporation and Pfizer Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Chevron Corporation Β· Energy
$188.52
-23.1% upside to fair value
Grade D
VS
Pfizer Inc. Β· Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric CVX PFE
Current Price $188.52 $26.91
Fair Value Estimate $145.00 $35.00
Upside to Fair Value -23.1% +30.1%
Market Cap $376.9B $153.0B
Forward P/E 22.9x 9.5x
EV / EBITDA 7.8x 13.8x
Price / Sales 1.5x 2.4x
Price / FCF 17.0x 16.8x
Revenue Growth YoY -4.6% -1.6%
Gross Margin 30.4% 70.3%
Operating Margin 9.0% 24.7%
Return on Equity 6.6% 9.0%
Dividend Yield 4.52% 6.4%
FCF Yield 5.89% 5.9%
Analyst Consensus Buy Hold
Investment Thesis
CVX β€” Chevron Corporation
Chevron Corporation is a leading integrated oil and gas major with global upstream and downstream operations, a fortress balance sheet, and a shareholder-friendly capital return program. Under CEO Mike Wirth, the company has prioritized disciplined capital allocation, returning over $27 billion to shareholders in 2024 alone through buybacks and dividends, while maintaining a 38-year streak of con…
PFE β€” Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric CVX PFE
Zone Low $108.75 $25.00
Zone High $123.25 $29.00
In Buy Zone? No Yes
← CVX Research    PFE Research β†’    All Research